Evidence map›Paper›PMID 34986176›Full record

ArticlePLoS neglected tropical diseases2022

The cost of tsetse control using 'Tiny Targets' in the sleeping sickness endemic forest area of Bonon in Côte d'Ivoire: Implications for comparing costs across different settings.

Fabrice Courtin, Dramane Kaba, Jean-Baptiste Rayaisse, Philippe Solano, Steve J Torr, Alexandra P M Shaw

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fabrice CourtinInstitut Pierre Richet (IPR), Institut National de Santé Publique (INSP), Laboratoire Mixte International sur les Maladies à Vecteurs, Bouaké, Côte d'Ivoire.ORCID 0000-0003-4920-316X
Dramane KabaInstitut Pierre Richet (IPR), Institut National de Santé Publique (INSP), Laboratoire Mixte International sur les Maladies à Vecteurs, Bouaké, Côte d'Ivoire.
Jean-Baptiste RayaisseInstitut de Recherche pour le Développement (IRD) UMR 177 Intertryp IRD-CIRAD, Université Montpellier, Montpellier, France.
Philippe SolanoInstitut de Recherche pour le Développement (IRD) UMR 177 Intertryp IRD-CIRAD, Université Montpellier, Montpellier, France.ORCID 0000-0002-4351-3506
Steve J TorrLiverpool School of Tropical Medicine (LSTM), Liverpool, Merseyside, United Kingdom.
Alexandra P M ShawDivision of Infection and Pathway Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-2919-5043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWork to control the gambiense form of human African trypanosomiasis (gHAT), or sleeping sickness, is now directed towards ending transmission of the parasite by 2030. In order to supplement gHAT case-finding and treatment, since 2011 tsetse control has been implemented using Tiny Targets in a number of gHAT foci. As this intervention is extended to new foci, it is vital to understand the costs involved. Costs have already been analysed for the foci of Arua in Uganda and Mandoul in Chad. This paper examines the costs of controlling Glossina palpalis palpalis in the focus of Bonon in Côte d'Ivoire from 2016 to 2017. METHODOLOGY/PRINCIPAL

findingsSome 2000 targets were placed throughout the main gHAT transmission area of 130 km2 at a density of 14.9 per km2. The average annual cost was USD 0.5 per person protected, USD 31.6 per target deployed of which 12% was the cost of the target itself, or USD 471.2 per km2 protected. Broken down by activity, 54% was for deployment and maintenance of targets, 34% for tsetse surveys/monitoring and 12% for sensitising populations. CONCLUSIONS/SIGNIFICANCE: The cost of tsetse control per km2 of the gHAT focus protected in Bonon was more expensive than in Chad or Uganda, while the cost per km2 treated, that is the area where the targets were actually deployed, was cheaper. Per person protected, the Bonon cost fell between the two, with Uganda cheaper and Chad more expensive. In Bonon, targets were deployed throughout the protected area, because G. p. palpalis was present everywhere, whereas in Chad and Uganda G. fuscipes fuscipes was found only the riverine fringing vegetation. Thus, differences between gHAT foci, in terms of tsetse ecology and human geography, impact on the cost-effectiveness of tsetse control. It also demonstrates the need to take into account both the area treated and protected alongside other impact indicators, such as the cost per person protected.

Indexed as

Tsetse FliesAnimalsChadCote d'IvoireEndemic DiseasesForestsHumansInsect ControlInsecticidesInsect VectorsTrypanosoma brucei gambienseTrypanosomiasis, AfricanUgandaInsecticides

Identifiers

PMID34986176
PMCPMC8730416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.